Vitamin C Supplementation Lowers Advanced Glycation End Products (Ages) and Malondialdehyde (Mda) in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Publisher



Rabizadeh S¹ ; Heidari F¹ ; Karimi R¹ ; Rajab A¹ ; Rahimidehgolan S¹ ; Yadegar A¹ ; Mohammadi F¹ ; Mirmiranpour H¹ ; Esteghamati A¹ ; Nakhjavani M¹ Show Affiliations
Source: Food Science and Nutrition Published:2023

Abstract

This study evaluated how daily vitamin C administration impacts systemic oxidative stress and inflammation and its safety in T2D patients. This randomized, double-blinded, placebo-controlled, parallel-arm clinical trial included 70 patients with T2D. They were allocated to receive either 500 mg/day of vitamin C or a matching placebo for 8 weeks. Of the 70 subjects assigned to the trial, 57 were included in the statistical analysis (vitamin C: n = 32, placebo: n = 25). Inflammatory and oxidative markers, including advanced glycation end products (AGEs), malondialdehyde (MDA), advanced oxidation protein products (AOPP), oxidized low-density lipoprotein (ox-LDL), highly sensitive C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), and ferric reducing ability of plasma (FRAP) were measured at baseline and the end of the trial. In addition, vitamin C tolerance was evaluated. A nutritionist visited all participants for a standard diabetic regimen. Following vitamin C supplementation, the serum levels of MDA (p-value <.001) and AGEs (p-value =.002) demonstrated a significant decrease after controlling for multiple confounders, including age, blood pressure, waist circumference, HbA1C, TG, and LDL-C, while no significant changes were observed for AOPP (p-value =.234) and ox-LDL (p-value =.480). The FRAP showed an increasing trend as an antioxidant marker but was not statistically significant (p-value =.312). The hs-CRP and TNF-α had no significant changes (p-value:.899 and.454, respectively). Also, no major adverse events were observed. Vitamin C supplementation may be beneficial in reducing AGEs and MDA in patients with T2D. © 2023 The Authors. Food Science & Nutrition published by Wiley Periodicals LLC.